Christopher Sullivan - 10 Dec 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Christopher Sullivan
Issuer symbol
AVTX
Transactions as of
10 Dec 2025
Transactions value $
-$636
Form type
4
Filing time
12 Dec 2025, 16:17:34 UTC
Previous filing
01 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sullivan Christopher Ryan Chief Financial Officer C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE /s/ Christopher Sullivan 12 Dec 2025 0001810417

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Tax liability -$636 -155 -0.89% $4.10 17.3K 10 Dec 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 417 additional shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.